Germany's BDS goes independent:
This article was originally published in Clinica
BDS International Diagnostics has been spun off from its US-based parent company, Polymedco, through a management buy-out. The new company, located in Schwetzingen, Germany, specialises in helping in vitro diagnostics and medical device suppliers to establish a foothold in European markets. Its services include searching, screening, selecting, training and managing a network of 1,800 distributors, with 650 in Europe. It also helps with regulatory issues. "Many of our international clients find it easier to meet Eastern European distributors this way, as they are often unable to attend trade fairs," George Skinner, director of sales and marketing at BDS International Diagnostics, told Clinica.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.